Article

A Semantic Approach for the Homogeneous Identification of Events in Eight Patient Databases: A Contribution to the European eu-ADR Project

LESIM, ISPED, Uni. Bordeaux 2, France.
Studies in health technology and informatics 01/2010; 160(Pt 2):1085-9. DOI: 10.3233/978-1-60750-044-5-190
Source: PubMed

ABSTRACT The overall objective of the EU-ADR project is the design, development, and validation of a computerised system that exploits data from electronic health records and biomedical databases for the early detection of adverse drug reactions. Eight different databases, containing health records of more than 30 million European citizens, are involved in the project. Unique queries cannot be performed across different databases because of their heterogeneity: Medical record and Claims databases, four different terminologies for coding diagnoses, and two languages for the information described in free text. The aim of our study was to provide database owners with a common basis for the construction of their queries. Using the UMLS, we provided a list of medical concepts, with their corresponding terms and codes in the four terminologies, which should be considered to retrieve the relevant information for the events of interest from the databases.

Download full-text

Full-text

Available from: Fleur Mougin, Aug 30, 2015
2 Followers
 · 
311 Views
  • Source
    • "95% confidence intervals were calculated assuming a normal binomial distribution. Age standardized rates were calculated based on the age distribution of the world population as presented by the WHO [38]. Additionally, incidence rates were reported for the pre-pandemic influenza period (January 2000–March 2009), the pandemic influenza but pre-vaccination period (April–September 2009), and the period after the start Table 1 Overview of databases and codes used for the calculation of incidence rates of narcolepsy diagnosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: In August 2010 reports of a possible association between exposure to AS03 adjuvanted pandemic A(H1N1)pdm09 vaccine and occurrence of narcolepsy in children and adolescents emerged in Sweden and Finland. In response to this signal, the background rates of narcolepsy in Europe were assessed to rapidly provide information for signal verification. METHODS: We used a dynamic retrospective cohort study to assess the narcolepsy diagnosis rates during the period 2000-2010 using large linked automated health care databases in six countries: Denmark, Finland, Italy, the Netherlands, Sweden and the United Kingdom. RESULTS: Overall, 2608 narcolepsy cases were identified in almost 280 million person years (PY) of follow up. The pooled incidence rate was 0.93 (95% CI: 0. 90-0.97) per 100,000 PY. There were peaks between 15 and 30 year of age (women>men) and around 60 years of age. In the age group 5-19 years olds rates were increased after the start of pandemic vaccination compared to the period before the start of campaigns, with rate ratios (RR) of 1.9 (95% CI: 1.1-3.1) in Denmark, 6.4 (95% CI: 4.2-9.7) in Finland and 7.5 (95% CI: 5.2-10.7) in Sweden. Cases verification in the Netherlands had a significant effect on the pattern of incidence over time. CONCLUSIONS: The results of this incidence study provided useful information for signal verification on a population level. The safety signal of increased narcolepsy diagnoses following the start of the pandemic vaccination campaign as observed in Sweden and Finland could be observed with this approach. An increase in narcolepsy diagnoses was not observed in other countries, where vaccination coverage was low in the affected age group, or did not follow influenza A(H1N1)pdm09 vaccination. Patient level analyses in these countries are being conducted to verify the signal in more detail.
    Vaccine 12/2012; 31(8). DOI:10.1016/j.vaccine.2012.12.015 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Initiatives to improve pharmacovigilance in Europe1 are essential in improving the safety of health care because current approaches to detecting adverse drug reactions have major limitations.Databases derived from electronic patient records and hospital administration systems could help to improve detection.2 We used one primary care database to investigate the association of myopathy and myalgia with the use of statins and fibrates.3 This case crossover …
    BMJ Clinical Research 12/2009; 340. DOI:10.1136/bmj.c2403 · 14.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this proof-of-concept paper we describe the framework, process, and preliminary results of combining data from European electronic healthcare record (EHR) databases for large-scale monitoring of drug safety. Aggregated demographic, clinical, and prescription data from eight databases in four countries (Denmark, Italy, Netherlands, the UK) were pooled using a distributed network approach by generation of common input data followed by local aggregation through custom-built software, Jerboa(©). Comparison of incidence rates of upper gastrointestinal bleeding (UGIB) and nonsteroidal anti-inflammatory drug (NSAID) utilization patterns were used to evaluate data harmonization and quality across databases. The known association of NSAIDs and UGIB was employed to demonstrate sensitivity of the system by comparing incidence rate ratios (IRRs) of UGIB during NSAID use to UGIB during all other person-time. The study population for this analysis comprised 19,647,445 individuals corresponding to 59,929,690 person-years of follow-up. 39,967 incident cases of UGIB were identified during the study period. Crude incidence rates varied between 38.8 and 109.5/100,000 person-years, depending on country and type of database, while age-standardized rates ranged from 25.1 to 65.4/100,000 person-years. NSAID use patterns were similar for databases within the same country but heterogeneous among different countries. A statistically significant age- and gender-adjusted association between use of any NSAID and increased risk for UGIB was confirmed in all databases, IRR from 2.0 (95%CI:1.7-2.2) to 4.3 (95%CI: 4.1-4.5). Combining data from EHR databases of different countries to identify drug-adverse event associations is feasible and can set the stage for changing and enlarging the scale for drug safety monitoring.
    Pharmacoepidemiology and Drug Safety 01/2011; 20(1):1-11. DOI:10.1002/pds.2053 · 3.17 Impact Factor
Show more